TEVA PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?
TEVA PHARM has three hundred and twenty-three approved drugs.
There are thirty-four US patents protecting TEVA PHARM drugs. There are forty-four tentative approvals on TEVA PHARM drugs.
There are four hundred and fifty-eight patent family members on TEVA PHARM drugs in thirty-seven countries and nine hundred and forty-five supplementary protection certificates in eighteen countries.
Summary for TEVA PHARM
| International Patents: | 458 |
| US Patents: | 34 |
| Tradenames: | 269 |
| Ingredients: | 261 |
| NDAs: | 323 |
| Patent Litigation for TEVA PHARM: | See patent lawsuits for TEVA PHARM |
| PTAB Cases with TEVA PHARM as petitioner: | See PTAB cases with TEVA PHARM as petitioner |
Drugs and US Patents for TEVA PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | TREPROSTINIL | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 206648-001 | Sep 26, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Usa Inc | CHLORZOXAZONE | chlorzoxazone | TABLET;ORAL | 212898-001 | Jun 17, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Teva Pharms Usa | VIGABATRIN | vigabatrin | FOR SOLUTION;ORAL | 209824-001 | Apr 23, 2018 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | DISCN | Yes | No | 9,731,087*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva Pharm | AIRDUO DIGIHALER | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-005 | Jul 12, 2019 | DISCN | Yes | No | 11,969,544*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEVA PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | 7,544,372 | ⤷ Sign Up |
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-001 | Jan 27, 2017 | 6,446,627 | ⤷ Sign Up |
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-004 | Feb 20, 2020 | 6,718,972 | ⤷ Sign Up |
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-005 | Feb 20, 2020 | 8,006,690 | ⤷ Sign Up |
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-003 | Jan 27, 2017 | 6,446,627 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
Premature patent expirations for TEVA PHARM
International Patents for TEVA PHARM Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3692021 | ⤷ Sign Up |
| Eurasian Patent Organization | 201300231 | ⤷ Sign Up |
| Eurasian Patent Organization | 037087 | ⤷ Sign Up |
| Mexico | 2016004316 | ⤷ Sign Up |
| Eurasian Patent Organization | 201991219 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TEVA PHARM Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435025 | 300995 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN GLYCOPYRRONIUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER GLYCOPYRRONIUYM BROMIDE, EN FORMOTEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER FORMOTEROL FUMARAAT DIHYDRAAT; REGISTRATION NO/DATE: EU/ 1/18/1339 20181220 |
| 2435024 | 2190014-7 | Sweden | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210 |
| 1419152 | 2012C/022 | Belgium | ⤷ Sign Up | PRODUCT NAME: RILPIVIRINE EN TENOFOVIR DISOPROXIL; AUTHORISATION NUMBER AND DATE: EU/1/11/737/001 20111128 |
| 3300601 | 2290030-2 | Sweden | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REG. NO/DATE: EU/1/18/1308 20180827 |
| 0740668 | C00740668/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: TADALAFILUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56018 04.05.2004 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
